Safusidenib not checked

Nuvation Bio · DS-1001b · AB-218

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.”In the company’s words, NCT05303519 on ClinicalTrials.gov
Tested for
Oligodendroglioma (3 trials), Glioma (2 trials), IDH1-mutant Glioma (2 trials), Astrocytoma IDH Mutant Grade 2 (2 trials), Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2 and 9 more
Main trialPhase 3
“This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized,…”In the company’s words, NCT05303519 on ClinicalTrials.gov
Other names
DS-1001b · Investigational · AB-218

Other drugs for Oligodendroglioma

All 7 drugs for Oligodendroglioma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 1 Dec 2028 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3Not yet recruiting May 2029 Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Phase 2Active, not recruiting 10 Mar 2023 A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Phase 2Recruiting Sep 2030 Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Phase 1Completed 31 Jan 2021 Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Phase 1Terminated 15 Aug 2024 IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Safusidenib

Following is part of Solo: you see every change to Safusidenib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in